Independent clinical consultancy ·
Drug development decisions that hold up to scrutiny.
Princeton MedSolutions is the consulting company of Dr. Roland Meier, M.D., Ph.D., an experienced drug developer in oncology with clinical training. Dr. Meier’s experience in pharmaceutical drug development ranges from first-inhuman to post-approval studies and medical affairs trials as well as pharmacovigilance.
Where the practice plugs in
One asset, four places it can stall.
Preclinical → IND
Clinical development
IDP, CDP, target product profile, protocol writing, health authority interaction.
Phase I → III
Pharmacovigilance
Case-level safety review, signal detection, benefit–risk, risk mitigation planning.
Filing → launch
Medical affairs
KOL identification and engagement, launch activity, registries, Phase II support.
Throughout
Medical writing
Protocols, safety documents, abstracts, peer-reviewed publications, congress decks.
Who you actually work with
Dr. Roland Meier, M.D., Ph.D.
Graduated from the University of Zurich with an M.D. and obtained an M.D., Ph.D. from the Université de Lausanne in pediatric oncology. After his post-doctoral fellowship at the Lawrence Berkeley National Laboratory in Berkeley, CA, he moved into industry through Medical Affairs, trained in pharmacovigilance, and then into clinical development.
He has worked across gene and cell therapies, immunology, radiotherapies and drug combinations, in rare disease, oncology, hematology and neuro-oncology. He has led launches of new drugs and indications, and built early access programmes that got life-extending therapies to patients sooner.
He has held leadership roles at major pharmaceutical companies and served as chief medical officer at startup biotechs. Engagements today are as independent clinical consultant, medical monitor, safety physician, or fractional CMO.
Bring the medical question early, not after the protocol is written.
Fractional CMO cover, a medical monitor for an ongoing trial, or a second read on a development plan — tell me what stage the asset is at.